Item request has been placed!

Item request cannot be made.

Processing Request

Search Results

Display Settings

Results per page: 10

Sort By: Relevance

Filter

Your Filters

Subject : tumor necrosis factors

Reset filters

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors.

Authors : Mease, Philip J.^1,2 (AUTHOR) ; Walsh, Jessica A.^3,4 (AUTHOR) ; Fitzgerald, Timothy P.⁵ (AUTHOR)

Source: Rheumatology & Therapy. Feb2026, Vol. 13 Issue 1, p115-134. 20p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.

Authors : Ogdie, Alexis¹ (AUTHOR) ; Reddy, Soumya M.² (AUTHOR); Gillespie, Sarah H.¹ (AUTHOR)

Source: Trials. 3/18/2025, Vol. 26 Issue 1, p1-15. 15p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis.

Authors : Petrovic, Aleksandra¹ (AUTHOR); Samuelsen, Victoria Marie¹ (AUTHOR); Davies, Richard¹ (AUTHOR)

Source: Clinical & Experimental Immunology. Dec2024, Vol. 218 Issue 3, p329-340. 12p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.

Authors : Mease, Philip J.¹ (AUTHOR) ; Warren, Richard B.² (AUTHOR); Nash, Peter³ (AUTHOR)

Source: Rheumatology & Therapy. Oct2024, Vol. 11 Issue 5, p1413-1423. 11p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Unveiling Sex-Related Variability in Psoriatic Arthritis: A Call for Personalized Care.

Authors : Baciu, Teodora¹ (AUTHOR); Neagu, Adriana Elena^1,2 (AUTHOR); Saulescu, Ioana Cristina^1,2 (AUTHOR)

Source: Journal of Clinical Medicine. Jun2025, Vol. 14 Issue 12, p4124. 19p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.

Authors : Mease, Philip J.¹ (AUTHOR) ; Warren, Richard B.² (AUTHOR); Nash, Peter³ (AUTHOR)

Source: Rheumatology & Therapy. Oct2024, Vol. 11 Issue 5, p1403-1412. 10p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.

Authors : Kivitz, Alan J.¹ (AUTHOR) ; Kremer, Joel M.² (AUTHOR); Legerton III, Clarence W.³ (AUTHOR)

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p675-689. 15p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.

Authors : Kristensen, Lars Erik^1,2 (AUTHOR) ; Deodhar, Atul³ (AUTHOR); Leung, Ying-Ying⁴ (AUTHOR)

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p487-499. 13p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.

Authors : Warren, Richard B.¹ (AUTHOR); McInnes, Iain B.² (AUTHOR); Nash, Peter³ (AUTHOR)

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p829-839. 11p.

Record details

Read Online Read More Add to Saved list

Academic Journal

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Authors : Mease, Philip J.¹ (AUTHOR); Warren, Richard B.² (AUTHOR); Nash, Peter³ (AUTHOR)

Source: Rheumatology & Therapy. Jun2024, Vol. 11 Issue 3, p817-828. 12p.

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors.

Guselkumab versus golimumab in patients with active psoriatic arthritis and inadequate response to an initial tumor necrosis factor inhibitor: study protocol for EVOLUTION, a pragmatic, phase 3b, open-label, randomized, controlled effectiveness trial.

Immune cell activity during anti-TNF treatment in patients with psoriasis and psoriatic arthritis.

Comparative Effectiveness of Bimekizumab and Ustekinumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.

Unveiling Sex-Related Variability in Psoriatic Arthritis: A Call for Personalized Care.

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.

Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison.

Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison.

Contact

Follow us